- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03275753
Visual Function Tests in Age-related Macular Degeneration
Visual Function Tests in Non-Exudative Age-Related Macular Degeneration and Normal Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Andover, Massachusetts, United States, 01810
- Andover Eye Associates
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Group 1: Normal Population (N=50) VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases.
Group 2: Early Dry AMD Population (N=50) VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD based on fundus features.
Group 3: Intermediate Dry AMD Population (N=50) VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD based on fundus features.
Group 4: Advanced Dry AMD Population (N=50) Clinical diagnosis of advanced dry AMD based on fundus features in the study eye
Description
Inclusion Criteria:
All Subjects Must:
- Be 60 years of age or older;
- Provide written informed consent;
- Be willing and able to follow all instructions and attend the study visits;
Must be able to perform all study procedures;
Normal Subjects:
- Have BCVA of 20/25 or better in the study eye;
Have no history or clinical evidence of AMD, retinal diseases or any other ocular pathologies in either eye;
AMD Subjects:
- Have BCVA of 20/40 or better in the study eye;
Have a clinical diagnosis of non-exudative AMD in the study eye;
Exclusion Criteria:
All subjects must not have any of the below criteria
- Have a diagnosis of wet AMD in the study eye;
- Have any other hereditary or acquired retinal diseases in either eye ;
- Have glaucoma or other optic nerve diseases in either eye;
- Have corneal or other anterior segment diseases in either eye;
- Have significant cataract in the study eye;
- Have a history of ocular trauma or ocular surgery (other than cataract removal) in the study eye;
- Have a history of uncontrolled systemic disease (e.g. poorly controlled hypertension or poorly controlled diabetes);
- Have a history of seizures;
- On psychotropic medications;
- Any other symptoms or conditions that could, in the opinion of the investigator, interfere with study procedures.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Normal Population
VA of 20/25 or better in the study eye with no prior diagnosis of any retinal or ocular diseases
|
All subjects will undergo a battery of visual function tests
|
|
Early Dry AMD Population
VA of 20/40 or better in the study eye with clinical diagnosis of early dry AMD
|
All subjects will undergo a battery of visual function tests
|
|
Intermediate Dry AMD Population
VA of 20/40 or better in the study eye with clinical diagnosis of intermediate dry AMD
|
All subjects will undergo a battery of visual function tests
|
|
Advanced Dry AMD Population
Clinical diagnosis of advanced dry AMD in the study eye
|
All subjects will undergo a battery of visual function tests
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Critical flicker fusion
Time Frame: At study visit through study completion, an average of 2 years
|
Critical flicker fusion will be tested using a computer based test for different stimulus colors, white, red, green and blue.
A wide range of luminance and contrast levels will be tested.
The subject would be seated in front of the monitor.
The non-study eye will be occluded.
Subjects would be given adequate practice tests prior to performing the actual test.
The stimulus will be presented on the monitor screen and the subject indicates perceiving the stimulus by pressing a test button.
|
At study visit through study completion, an average of 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dark adaptation
Time Frame: At study visit through study completion, an average of 2 years
|
Dark adaptation function will be assessed with dilated pupils using computer based stimuli following photo bleach.
Subject will be seated in front of the test monitor with best correction in place for the study eye.
The subject will be instructed to keep fixating on a red fixation cross in the center of the monitor and respond to perceiving the stimulus presented by pressing the response trigger button.
All stimuli will be presented in random order for all intensities presented.
The stimulus intensity is programmed to decrease in intensity with time.
The test will be terminated after 20 minutes of recording.
Dark adaptation curve will be generated and rod-cone recovery time (in minutes) will be derived from the curve.
|
At study visit through study completion, an average of 2 years
|
|
Reading Tests
Time Frame: At study visit through study completion, an average of 2 years
|
Reading tests will be performed using an electronic tablet device.
The subject will be seated in a comfortable position with the non-tested eye occluded.
The tablet will be set up in a table right in front of the subject at a viewing distance of 40cm.
The subject will be given detailed instructions on the test procedures and outcomes.
The goal of this test to assess reading speed of the study eye under a variety of conditions such as high contrast-high luminance, low contrast, low luminance, crowded letters, pepper words of different lengths and vanishing optotypes.
Each challenge will be tested using a different passage of similar difficulty level.
For each passage, reading speed will be estimated as the time taken to accurately read the entire passage and recorded in words per minute (WPM).
|
At study visit through study completion, an average of 2 years
|
|
Color vision function
Time Frame: At study visit through study completion, an average of 2 years
|
Color vision function will be assessed to test L, M and S cone functions.
During the test, a letter will briefly flash on the screen.
The subject then must verbally identify the letter and/or its orientation.
The response of the subject is then recorded by the technician.
If correct, the next letter is presented at decreased color contrast relative to the background.
The test continues in this manner until the subject incorrectly identifies the presented letter.
At that point, the stimulus is presented at the next higher contrast level.
This continues until the subject correctly identifies the presented letter.
The test then terminates.
|
At study visit through study completion, an average of 2 years
|
|
Shape discrimination
Time Frame: At study visit through study completion, an average of 2 years
|
Shape discrimination will be tested by presenting a two-alternative forced choice stimulus to the subject on a computer device (monitor or tablet).
The subject will be asked to identify the stimulus which is modulated and which is not.
The test shall be performed at full room lighting for photopic sensitivity as well as in reduced lighting (mesopic) conditions.
The effect of eccentricity may be tested by presenting successively larger targets with foveal fixation.
|
At study visit through study completion, an average of 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jason Chin, OD, ORA, Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17-270-0001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Age Related Macular Degeneration
-
Novartis PharmaceuticalsTerminatedNeovascular Age-Related Macular DegenerationRussian Federation
-
Novartis PharmaceuticalsCompletedNeovascular Age-Related Macular DegenerationSpain, Italy, Germany, Canada, Ireland
-
Hoffmann-La RocheWithdrawnNeovascular Age-Related Macular DegenerationDenmark, Argentina, Hong Kong, Thailand, Portugal, Greece, Spain
-
Regeneron PharmaceuticalsCompletedNeovascular Age Related Macular DegenerationUnited States
-
Hui PengNot yet recruitingNeovascular Age-related Macular Degeneration(nAMD)
-
Rophibio, Inc.Not yet recruitingNeovascular Age-related Macular Degeneration (nAMD)United States
-
Hoffmann-La RocheRecruitingNeovascular Age-Related Macular DegenerationAustria, Germany, Spain, Israel, France, Taiwan, Belgium, United Kingdom, United States, Argentina, Italy, Australia, Switzerland, Brazil, Turkey (Türkiye)
-
Innostellar Biotherapeutics Co.,LtdActive, not recruitingNeovascular Age-Related Macular DegenerationChina
-
Ophthotech CorporationCompletedNeovascular Age-Related Macular DegenerationUnited States
-
IVERIC bio, Inc.TerminatedNeovascular Age-Related Macular Degeneration
Clinical Trials on Visual Function Tests
-
Hospices Civils de LyonTerminated
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
University of Maryland, College ParkVanderbilt University; National Institute on Deafness and Other Communication...Enrolling by invitationAging | Hearing Loss | Hearing Loss, Sensorineural | Cochlear Hearing LossUnited States
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Portsmouth Hospitals NHS TrustRecruitingAsthmaUnited Kingdom
-
University Hospital, BrestCompletedRadiotherapy; Complications | Cancer, LungFrance
-
Shandong UniversityShandong Provincial Hospital; Qianfoshan Hospital; Traditional Chinese Medicine... and other collaboratorsUnknownImmune ThrombocytopeniaChina
-
Yaron Har-ShaiUnknownBreast Reconstruction | Respiratory FunctionIsrael
-
Fondation Ophtalmologique Adolphe de RothschildCompleted